A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter, Parallel-Group Study to Investigate the Safety, Tolerability, and the Effect of RO7269162 on Amyloid and Non-Amyloid Disease-Related Biomarkers following Daily Oral Administration in Participants at Risk for or at the Prodromal Stage of Alzheimer’s Disease
Active, not recruitingCTIS2023-506183-13-00
F. Hoffmann-La Roche AGAlzheimer’s Disease
Start: 2024-03-29Target: 202Updated: 2025-12-18